通过虚拟查和网络药理学方法发现治疗静脉疾病的潜在化合物
Oscar Salvador Barrera-Vázquez1, Juan Luis Escobar-Ramírez1, Jacinto Santiago-Mejía1
1Department of Pharmacology, Faculty of Medicine, University National Autonomous of Mexico (UNAM), Mexico City 04510, Mexico.
Molecules (Basel, Switzerland)
|December 23, 2023
概括
虚拟查确定了对静脉疾病 (VD) 的潜在治疗化合物. 柏柏林在急性静脉高血压模型中显示出有前途的活性,为治疗提供了一个新的途径.
科学领域:
- 药理学和计算化学
- 静脉疾病研究 静脉疾病研究
背景情况:
- 周围静脉高血压是静脉疾病 (VD) 的一个关键特征,导致下肢胀.
- 目前的类药物在减少胀和改善生活质量方面具有有限的有效性.
研究的目的:
- 通过虚拟查,识别具有治疗静脉疾病潜力的新型分子.
- 在实验模型中评估已识别的化合物的疗效.
主要方法:
- 从多个数据库中对超过41,000种化合物的虚拟选.
- 使用计算工具 (rcdk,chemminer,Cytoscape) 进行指纹分析和目标识别.
- 专注于与VD网络相互作用并具有多目标能力的化合物.
主要成果:
- 从84个与VD网络相互作用的潜在候选分子中确定了18个.
- 柏柏林因其可负担性和现有文献支持而被选择进行实验评估.
- 实验结果在急性静脉高血压模型中证实了柏柏林的活性.
结论:
- 虚拟查是发现静脉疾病潜在治疗剂的有效方法.
- 柏柏林在治疗静脉高血压方面显示出治疗潜力.
- 对贝贝林和其他已识别的化合物进行进一步的研究是有必要的,用于治疗静脉疾病.
相关概念视频
Drug Discovery: Overview
7.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
706
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
706
Structure-Activity Relationships and Drug Design
727
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
727
Protein Networks
4.0K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.0K
Targets for Drug Action: Overview
6.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K


